AOD-9604 and Bone Health: What Women Need to Know About This HGH Fragment

What Is AOD-9604 and Why Are Women Asking About It?

AOD-9604 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone (HGH) sequence. Researchers isolated this C-terminal fragment because it appears to retain the lipolytic (fat-burning) properties of full-length HGH without activating the growth hormone receptor responsible for IGF-1 elevation and the metabolic risks that follow. The compound has generated real interest among women who are using compounded peptide protocols for weight management and body composition, and some providers have suggested it may also support bone density. That claim deserves careful examination.

Growth hormone and its downstream mediator IGF-1 do influence bone remodeling. Osteoblast activity, periosteal expansion, and trabecular bone density all depend in part on adequate GH and IGF-1 signaling across the lifespan. Because AOD-9604 is a fragment of HGH, the assumption that it shares bone-related properties seems logical, but the molecular evidence does not support it clearly, at least not yet.

Women ask about this compound at every life stage, from reproductive-age women managing PCOS-related metabolic concerns to perimenopausal women watching their DEXA scores decline. Each group has a different risk profile for bone loss and a different threshold for what counts as an acceptable evidence gap.

How AOD-9604 Works: The Receptor Story Matters for Bone

The Lipolytic Mechanism

Heffernan et al. (Endocrinology, 2001) demonstrated in animal models that AOD-9604 stimulates lipolysis and inhibits lipogenesis through a mechanism that does not depend on binding the classical GH receptor. This finding was significant because it suggested the fragment could reduce adiposity without the IGF-1-mediated side effects of full-length HGH, including glucose intolerance and potential oncogenic risk.

What This Means for Bone

The GH receptor pathway that AOD-9604 bypasses is one of the main routes by which growth hormone supports bone formation. Full-length GH binds its receptor on osteoblasts and in the liver, driving IGF-1 production. IGF-1 then stimulates osteoblast proliferation, collagen synthesis, and bone mineralization. Studies in IGF-1-deficient animal models consistently show reduced bone mineral density and impaired cortical bone geometry. If AOD-9604 does not activate the GH receptor, it may not trigger this cascade at all.

That is the central tension in the AOD-9604 and bone conversation. The peptide's selling point (receptor independence) is also the reason its bone benefits cannot be assumed.

Beta-3 Adrenergic Receptor Involvement

Some early animal research suggested AOD-9604 may interact with beta-3 adrenergic receptors in adipose tissue. Beta-3 adrenergic signaling is not a recognized primary driver of bone remodeling in women, so this pathway does not provide a plausible bridge to bone benefit. No published human pharmacology study has mapped the peptide's receptor interactions in bone tissue specifically.

The Evidence on AOD-9604 and Bone Density: Honest Assessment

To evaluate AOD-9604's bone impact fairly, it helps to separate four categories of evidence: direct human bone data, indirect human metabolic data, animal bone data, and theoretical mechanisms. Here is where each stands as of early 2025.

Direct Human Bone Data

None exists. No published randomized controlled trial, observational cohort, or even a case series has measured bone mineral density (BMD) or bone turnover markers (such as osteocalcin, P1NP, or CTX) as primary or secondary outcomes in humans taking AOD-9604. Any provider claiming this compound is proven to support bone health in women is extrapolating well beyond the available literature.

Indirect Human Metabolic Data

AOD-9604 reached Phase II clinical trials for obesity in the early 2000s under the development program by Metabolic Pharmaceuticals. Those trials documented modest effects on body weight and were generally well-tolerated over 12 weeks, but bone outcomes were not measured. The program did not progress to Phase III, and no regulatory approval was obtained anywhere in the world for any indication.

Animal Bone Data

A small number of preclinical studies have examined HGH and its fragments in rodent bone models. The full HGH molecule consistently improves bone density in GH-deficient animals. Fragments including the 176-191 region have not demonstrated equivalent anabolic effects on bone in published animal studies. This absence of positive preclinical bone data is a meaningful signal, not a neutral one.

Theoretical Mechanisms That Do Not Hold Up

Proponents sometimes argue that because AOD-9604 reduces visceral adiposity, and because excess visceral fat is negatively associated with bone quality in women, the peptide should indirectly support bone health. The logic is not entirely wrong. Research published in the Journal of Bone and Mineral Research has found that visceral fat is independently associated with lower bone strength even when total BMD appears preserved. Reducing visceral fat could theoretically reduce the marrow fat infiltration that impairs bone quality. However, this chain of reasoning involves multiple untested steps and cannot substitute for direct evidence.

Bone Health Across Women's Life Stages: Where AOD-9604 Fits (and Does Not)

Reproductive Years (Ages 18 to 40)

Women in their reproductive years are generally accruing or maintaining peak bone mass. The immediate bone risk from AOD-9604 in this group is likely low, but the absence of safety data means there is no basis for using it prophylactically for bone. Women in this stage who are considering AOD-9604 for fat loss should know that peak bone mass is largely set by age 30, and any intervention that might interfere with normal hormonal signaling during this window carries theoretical risk.

PCOS is a relevant condition here. Women with PCOS often have altered IGF-1 signaling, and some studies show lower trabecular bone density in PCOS despite higher androgen levels. Whether AOD-9604 would help or harm bone in this context is entirely unknown.

Perimenopause (Typically Ages 45 to 55)

This is the highest-stakes life stage for this conversation. Women lose 2 to 3 percent of bone mineral density per year in the first three to five years after menopause, driven by the collapse in estrogen that follows the final menstrual period. The perimenopausal transition, which can begin 7 to 10 years earlier, also sees declining estrogen and increasingly disordered GH pulsatility.

Adding an unproven peptide to a period of rapid bone loss without evidence of benefit is not a reasonable clinical choice. Perimenopausal women asking about AOD-9604 for bone health deserve a direct answer: the evidence does not support it, and there are proven therapies available, including menopausal hormone therapy and bisphosphonates, with extensive trial data specifically in women.

Post-Menopause

The North American Menopause Society (NAMS) 2023 position statement on menopause hormone therapy affirms that estrogen-based HRT reduces bone loss and fracture risk in recently menopausal women, with the strongest evidence for women under 60 or within 10 years of menopause onset. This is a well-studied, guideline-supported intervention. AOD-9604 is not comparable, and it is not a substitute for established therapies in post-menopausal women with osteopenia or osteoporosis.

Trying to Conceive and Periconception

See the dedicated pregnancy section below. AOD-9604 should not be used in this window.

Sex-Specific Pharmacology: What We Know (and Do Not Know) About AOD-9604 in Women

Human growth hormone has sex-dimorphic secretion patterns. Women secrete GH in higher-amplitude pulses than men and have greater total 24-hour GH output, driven partly by estrogen-stimulated GH release. This sex difference influences IGF-1 levels, hepatic GH receptor density, and ultimately bone metabolism. Men and women also differ in how adipose tissue responds to GH-mediated lipolysis: estrogen modulates adipose sensitivity to adrenergic stimulation, which may change how fragments like AOD-9604 act on fat depots.

No pharmacokinetic or pharmacodynamic studies of AOD-9604 have been conducted specifically in women. The Heffernan et al. Animal studies used both male and female animals but did not report sex-disaggregated results for bone outcomes. This is a genuine evidence gap. Extrapolating male-default animal data to perimenopausal women is particularly unreliable because the estrogen milieu changes both GH axis function and bone remodeling dynamics in ways that animal models do not capture well.

Women have been historically underrepresented in peptide pharmacology research. That omission matters here because the population most likely to seek AOD-9604 for weight and body composition, women in midlife, is the group with the least direct trial data.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated during pregnancy.

No human pregnancy safety data exists. Animal developmental toxicology studies sufficient to characterize teratogenic risk have not been published in the peer-reviewed literature. Peptide hormones and hormone-derived fragments can cross the placenta depending on molecular size and transport mechanisms. At 15 amino acids and approximately 1,815 daltons, AOD-9604 is within the molecular weight range where placental transfer is plausible.

Growth hormone axis modulation during pregnancy carries real theoretical risk. GH and IGF-1 are critical for normal fetal growth, particularly skeletal development. Any compound that alters GH signaling, even indirectly, should be avoided during fetal organogenesis (weeks 6 to 10) and the entire period of fetal bone modeling. ACOG recommends against using any compound with insufficient pregnancy safety data during gestation.

Lactation: Peptide transfer into breast milk has not been studied for AOD-9604. Given the lack of data, breastfeeding women should not use this compound. A newborn's GH axis is active and poorly buffered; exposure to exogenous peptides during this period is not without potential consequence.

Contraception requirement: Women of reproductive age using AOD-9604 as part of a compounded peptide protocol should use reliable contraception. The compound has not been assigned an FDA pregnancy category because it has never received FDA approval. Providers prescribing it through 503A compounding pharmacies operate outside a formal teratogenicity data framework.

If you are trying to conceive, currently pregnant, or breastfeeding, do not use AOD-9604. Discontinue at least one full menstrual cycle before a planned conception attempt, and ideally longer given the unknown clearance dynamics.

Who This May Be Right For vs. Who Should Avoid It

Women for Whom AOD-9604 Might Be Considered (With Appropriate Caveats)

AOD-9604 sits in a compounded peptide category used off-label for body composition. A woman might discuss it with a knowledgeable provider if she:

• Is not pregnant, not breastfeeding, and not trying to conceive
• Has a BMI <40 and is pursuing adjunct fat-loss support alongside diet and exercise
• Has been counseled that the compound is investigational, not approved, and carries unknown long-term risk
• Is not relying on it for bone health, which is not a supported indication

Even in this context, the conversation should include a frank discussion of what is not known. The compound is not FDA-approved, the bone claim specifically has no human trial support, and long-term safety data in women does not exist.

Women Who Should Avoid AOD-9604

• Pregnant women (contraindicated)
• Breastfeeding women (insufficient safety data)
• Women trying to conceive (avoid until adequate washout and conception)
• Post-menopausal women with osteopenia or osteoporosis seeking bone support (use evidence-based therapies instead)
• Women with active cancer or a history of hormone-sensitive malignancy (GH-axis peptides as a category carry theoretical proliferative risk)
• Women with untreated hypothyroidism (thyroid status affects GH axis function and bone turnover; stabilize thyroid disease first)

What Actually Works for Bone Health in Women: The Evidence-Backed Alternatives

Because AOD-9604 is being marketed to some women as a bone-supportive therapy, it is worth naming what the evidence actually supports.

Menopausal hormone therapy (MHT/HRT): Estrogen therapy remains the most effective non-bisphosphonate intervention for preserving bone in recently menopausal women. The Women's Health Initiative (WHI) confirmed that conjugated equine estrogen reduced hip fracture risk by 33 percent over 5.6 years of use. For women under 60 or within 10 years of menopause who do not have contraindications, MHT addresses both symptoms and bone loss simultaneously.

Bisphosphonates (alendronate, risedronate, zoledronic acid): These remain first-line pharmacologic therapy for osteoporosis. Alendronate 70 mg weekly reduces vertebral fracture risk by approximately 47 percent and hip fracture risk by 51 percent in women with established osteoporosis.

Calcium and vitamin D: Adequate calcium (1,000 to 1,200 mg daily depending on age) and vitamin D (1,500 to 2,000 IU daily in women at risk of deficiency) remain foundational. The USPSTF notes that supplementation alone does not substantially reduce fracture risk in community-dwelling women without deficiency, but correcting deficiency is a prerequisite to any bone-building strategy.

Resistance exercise: Progressive resistance training increases bone mineral density at the spine and hip in post-menopausal women. A 2022 meta-analysis in Osteoporosis International found that resistance training produced a mean BMD gain of 1.03 percent at the lumbar spine in post-menopausal women across 18 trials.

Current Clinical and Regulatory Status of AOD-9604

AOD-9604 is not approved by the FDA for any indication. It is available in the United States only through 503A compounding pharmacies, which produce it for individual patients under a valid prescription. In 2015, the FDA placed AOD-9604 on the list of bulk drug substances requiring further review, which limited its use in certain compounding contexts. Its current compounding status should be confirmed with the prescribing provider and pharmacy at the time of any prescription.

In Australia, where Metabolic Pharmaceuticals (later Calzada) conducted early clinical work, the compound also did not reach regulatory approval. The Australian Register of Therapeutic Goods does not list an approved product containing AOD-9604 as of 2025.

"The absence of evidence is not the same as evidence of absence, but in bone health medicine, where we have decades of fracture-endpoint trial data for approved agents, asking women to use an unapproved peptide fragment for bone support asks them to accept a risk-benefit calculation with only one side of the equation filled in," says Dr. Elena Vasquez, MD, WomanRx Clinical Reviewer and board-certified OB-GYN.

What to Ask Your Provider Before Starting AOD-9604

Before filling any compounded peptide prescription, ask your provider these specific questions:

1. What human clinical trial data supports this compound for the outcome I care about?
2. Is the compounding pharmacy 503A or 503B accredited, and have they provided a certificate of analysis?
3. What is the monitoring plan: labs, imaging, or both?
4. If I want bone support specifically, why is this compound preferred over evidence-based therapies?
5. What is the washout protocol if I decide to try to conceive?

Get the answers in writing. A provider who cannot name a specific trial or who dismisses the evidence gap question is a signal to seek a second opinion.